NOVEL EFFICIENT INHIBITOR OF KINASE 4, ASSOCIATED WITH INTERLEUKIN-1 (IRAK4) Russian patent published in 2017 - IPC C07D417/14 A61K31/506 A61P29/00 A61P11/06 A61P25/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of N-(6-((1-((2-ethylpyrimidin-5-yl)methyl)piperidin-4-yl)methyl)pyridin-2-yl)-5-methylthiazol-2-amine or its pharmaceutically acceptable salt, solvate or hydrate. Compound according to invention is intended for preparing a pharmaceutical composition for treating and/or preventing a pathological condition, associated with aberrant activity of IRAK4 kinase. Pharmaceutical composition for treating and/or preventing a pathological condition, associated with aberrant activity of IRAK4 kinase, is characterized by that it contains a therapeutically effective amount of compound according to invention and pharmaceutically acceptable carrier, solvent and/or filler. Pathological condition associated with aberrant activity of IRAK4 kinase is an immune inflammatory disease or oncological disease.

EFFECT: technical result is production of N-(6-((1-((2-ethylpyrimidin-5-yl)methyl)piperidin-4-yl)methyl)pyridin-2-yl)-5-methylthiazol-2-amine or its pharmaceutically acceptable salt, solvate or hydrate as a selective IRAK4 kinase inhibitor.

13 cl, 10 dwg, 2 tbl